pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$NBIXNEUROCRINE BIOSCIENCES INC

$NBIX165.31-1.25%
San Diego, CA, USupdated 14h ago

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
6
marketed
2
phase 3
2
catalysts ytd
6
approvals ytd
1
recalls ytd
0

Pipeline(6)

pipeline depth6 products
Preclinical: 1Phase 3: 2Marketed: 2Unknown: 1
1Preclinical2Phase 32Marketed1Unknown
Marketed
VALBENAZINE TOSYLATE
Chorea
Marketed
crinecerfont
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome)
Phase 3
direclidine citrate
Schizophrenia
Phase 3
hydrocortisone MR
Congenital Adrenal Hyperplasia (Adrenogenital Syndrome)
Preclinical
NBIP-2118
Obesity
drug
INGREZZA SPRINKLE
1 INDICATIONS AND USAGE INGREZZA and INGREZZA SPRINKLE ar…
Synaptic vesicular amine transporter

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (2)
Nov 2, 2026
earnings
$NBIX165.31-1.25%
15d ago
NEUROCRINE BIOSCIENCES INC earnings
NEUROCRINE BIOSCIENCES INC
→
Oct 28, 2026
earnings
$NBIX165.31-1.25%
20d ago
NEUROCRINE BIOSCIENCES INC earnings
NEUROCRINE BIOSCIENCES INC
→
view all catalysts →

Active trials

  • phase2Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEEterminatedn=8
  • phase2Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adult Participants With Classic Congenital Adrenal Hyperplasia (CAH)not yet recruitingn=36
  • phase3NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)recruitingn=200
  • phase2A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disordercompletedn=73
  • phase3Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsycompletedn=86
  • phase2Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesiarecruitingn=100
  • phase3Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)recruitingn=850
  • phase2Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Oldnot yet recruitingn=20
🐶 Hiring Signal
No open roles indexed yet — view NEUROCRINE BIOSCIENCES INC jobs →

News

  • Neurosterix nabs $105M, recruits Karuna veterans for schizophrenia push
    Addex Therapeutics spinout Neurosterix will use the series B funds to advance an oral drug targeting M4, a muscarinic receptor also targeted by BMS’ Cobenfy, which introduced a new mechanism for tr…
    biospace · 4d ago
  • With an approval apiece, the verdict is still out on AbbVie’s and BMS’ twin neuro buys
    After emraclidine’s schizophrenia fail and Cobenfy’s laggard launch, it’s too early to know who made the better buy: AbbVie, in its $8.7 billion Cerevel takeover in late 2023, or Bristol Myers Squi…
    biospace · 8d ago
  • STAT+: Who will get the first psychedelic approved?
    The biotech Compass Pathways has been seen as one of the frontrunners in the race to get the first psychedelic drug approved. But it could be a tight race, with a non-profit…
    stat · 13d ago
  • Neurocrine defends Prader-Willi drug after another patient death
    Neurocrine Biosciences will conduct a new study for the rare disease drug Vykat to explore dosing and safety in patients with Prader-Willi syndrome who have complex health issues.
    biospace · 13d ago
  • FDA uncages Aardvark’s Prader-Willi study after new data cleared safety concerns
    After cardiac safety signals led to a full clinical hold on Aardvark Therapeutics’ studies of ARD-101, the biotech conducted an additional safety study, in which no cardiac events were detected. Aa…
    biospace · 24d ago
  • STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancer
    Verastem Oncology reports encouraging early results for its KRAS G12D inhibitor, which it’s studying in more than 200 patients with advanced solid tumors like metastatic pancreatic ductal adenocarc…
    stat · 1mo ago
  • After a melanoma diagnosis, mRNA cancer vaccine delivered a patient hope — and a path forward
    A schoolteacher diagnosed with melanoma provides an inside look at what it was like to be treated with a cancer vaccine developed by Merck and Moderna.
    stat · 1mo ago
  • Compass Pathways CEO: Psychedelics company will ‘go slow before we go fast’
    The CEO of Compass Pathways said the company, whose psychedelic therapy is set for regulatory review this year, is prepared to “go slow before we go fast.”
    stat · 1mo ago
  • STAT+: FDA adcomm members’ ties to industry under scrutiny
    New research found that nearly 40% of FDA advisory meetings held over a recent 20-year period included either a patient or consumer rep with active ties to an advocacy group…
    stat · 1mo ago
  • STAT+: Pharmalittle: We’re reading about concerns over a rare disease drug, pharma payments to docs, and more
    Patient advocates and some experts are expressing growing alarm over the perceived risks of a Neurocrine Biosciences rare disease drug
    stat · 1mo ago
view all news mentions →
identifiers
ticker
$NBIX
SEC CIK
0000914475
country
US
source
sec_tickers
top tags
Obesity1Schizophrenia1
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 48m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?